# Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

> **NCT06059118** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 50 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** DFMO
- **DRUG:** testosterone cypionate
- **DRUG:** Luteinizing hormone-releasing hormone (LHRH) analogue
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT06059118
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-04
- **Primary completion:** 2027-01-04
- **Final completion:** 2029-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06059118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06059118, "Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06059118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*